Education
About Us
Working with TipRanks
Follow Us
Checkpoint Therapeutics (CKPT)
NASDAQ:CKPT
Total Valuation
Checkpoint Therapeutics has a market cap or net worth of $370.71M. The enterprise value is $325.19M.
Market Cap$370.71M
Enterprise Value$325.19M
Share Statistics
Checkpoint Therapeutics has 44,620,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding44,620,000
Owned by Insiders14.01%
Owned by Institutions24.33%
Financial Efficiency
Checkpoint Therapeutics’s return on equity (ROE) is 4.45 and return on invested capital (ROIC) is 444.94%.
Return on Equity (ROE)4.45
Return on Assets (ROA)-7.53
Return on Invested Capital (ROIC)444.94%
Return on Capital Employed (ROCE)4.45
Revenue Per Employee1.71K
Profits Per Employee-2.34M
Employee Count24
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Checkpoint Therapeutics is -2.26. Checkpoint Therapeutics’s PEG ratio is -0.45.
PE Ratio-2.26
PS Ratio0.00
PB Ratio15.24
Price to Fair Value-10.06
Price to FCF-9.87
Price to Operating Cash Flow-6.84
PEG Ratio-0.45
Income Statement
In the last 12 months, Checkpoint Therapeutics had revenue of 41.00K and earned -56.24M in profits. Earnings per share was -1.42.
Revenue41.00K
Gross Profit41.00K
Operating Income-56.17M
Pretax Income-56.24M
Net Income-56.24M
EBITDA-56.17M
Earnings Per Share (EPS)-1.42
Cash Flow
In the last 12 months, operating cash flow was -36.31M and capital expenditures 0.00, giving a free cash flow of -36.31M billion.
Operating Cash Flow-36.31M
Free Cash Flow-36.31M
Free Cash Flow per Share-0.81
Dividends & Yields
Checkpoint Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.52
52-Week Price Change136.67%
50-Day Moving Average4.11
200-Day Moving Average3.36
Relative Strength Index (RSI)79.31
Average Volume (3m)1.74M
Important Dates
Checkpoint Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Checkpoint Therapeutics as a current ratio of 0.37, with Debt / Equity ratio of 0.00%
Current Ratio0.37
Quick Ratio0.37
Debt to Market Cap0.00
Net Debt to EBITDA0.12
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Checkpoint Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Checkpoint Therapeutics EV to EBITDA ratio is -2.14, with an EV/FCF ratio of -3.87.
EV to Sales2.94K
EV to EBITDA-2.14
EV to Free Cash Flow-3.87
EV to Operating Cash Flow-3.87
Balance Sheet
Checkpoint Therapeutics has $33.04M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$33.04M billion.
Cash & Marketable Securities$33.04M
Total Debt$0.00
Net Cash-$33.04M
Net Cash Per Share-$0.74
Tangible Book Value Per Share-$0.32
Margins
Gross margin is 0.00%, with operating margin of -137009.76%, and net profit margin of -137170.73%.
Gross Margin0.00%
Operating Margin-137009.76%
Pretax Margin-137170.73%
Net Profit Margin-137170.73%
EBITDA Margin-137009.76%
EBIT Margin-137009.76%
Analyst Forecast
The average price target for Checkpoint Therapeutics is $4.45, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.45
Price Target Upside4.46% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-60.19%
EPS Growth Forecast56.60%